Attovia Therapeutics files for Nasdaq IPO to fund immune-disease biologics

Tao Fu's San Carlos biotech is seeking an ATTO listing before disclosing price range, share count or valuation.

By · Published

Primary source: Reuters

Why it matters

Attovia's filing shows the biotech IPO window is open enough for platform companies again, but only if public investors accept early clinical data and a long funding road.

Illustration of Attovia Therapeutics of San Carlos filing for a Nasdaq IPO to fund development of immune-disease biologics led by Tao Fu.

Attovia Therapeutics filed for a U.S. IPO on July 14th, putting founder and CEO Tao Fu's three-year-old immune-disease biologics company on track for a Nasdaq Global Market listing under the ticker ATTO, Reuters reported.…

Reader comments

Conversation for this story loads after sign-in.